Dynavax Technologies (DVAX) 10.91 $DVAX INVESTO
Post# of 273257
Posted On: 09/03/2016 9:23:01 AM
Dynavax Technologies (DVAX) 10.91 $DVAX
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Dynavax Technologies Corporation and Advises Investors to Contact the Firm
BusinessWire - Fri Sep 02, 6:51PM CDT
Goldberg Law PC announces that it is investigating Dynavax Technologies Corporation ("Dynavax" or the "Company"
(Nasdaq: DVAX) concerning possible violations of federal securities laws.
DVAX: 10.91 (-5.03)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Dynavax Technologies Corporation - DVAX
BusinessWire - Fri Sep 02, 5:25PM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dynavax Technologies Corporation (NASDAQ
VAX) resulting from allegations that Dynavax may have issued materially misleading business information to the investing public.
DVAX: 10.91 (-5.03)
Dynavax Reports Second Quarter 2016 Financial Results
Marketwire Canada - Fri Aug 05, 4:52PM CDT
BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016.
DVAX: 10.91 (-5.03)
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Marketwire Canada - Fri Aug 05, 4:32PM CDT
Advisory Committee Meeting Scheduled for November 16, 2016
DVAX: 10.91 (-5.03)
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 10.91 (-5.03), HRTX: 17.70 (-0.63), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)
Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 10.91 (-5.03), JNJ: 119.32 (+0.24), HRTX: 17.70 (-0.63), GILD: 76.89 (-0.53), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
Marketwired - Sat Jun 11, 10:00AM CDT
Pivotal Phase 3 Data Show Investigational Two-Dose Hepatitis B Vaccine Provides a Significantly Higher Rate of Seroprotection Than an Approved Vaccine in Patients With Type 2 Diabetes
DVAX: 10.91 (-5.03)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 10.91 (-5.03), PACB: 8.28 (-0.02), AVXL: 3.05 (+0.02), PPHM: 0.38 (+0.02)
Dynavax to Present at Two Upcoming Investor Conferences
Marketwired - Wed May 18, 6:01AM CDT
BERKELEY, CA--(Marketwired - May 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows:
DVAX: 10.91 (-5.03)
Dynavax Technologies Down 16.5% Since SmarTrend Downtrend Call (DVAX)
Comtex SmarTrend(R) - Fri May 13, 1:38PM CDT
SmarTrend identified a Downtrend for Dynavax Technologies (NASDAQVAX) on April 27th, 2016 at $18.36. In approximately 2 weeks, Dynavax Technologies has returned 16.54% as of today's recent price of $15.32.
DVAX: 10.91 (-5.03)
Dynavax Technologies reports 1Q loss
Automated Insights - Mon May 09, 8:05AM CDT
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Monday reported a loss of $27 million in its first quarter.
DVAX: 10.91 (-5.03)
Dynavax Reports First Quarter 2016 Financial Results
Marketwire Canada - Mon May 09, 8:02AM CDT
BERKELEY, CA--(Marketwired - May 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.
DVAX: 10.91 (-5.03)
Does This Upstart Pose a Threat to GlaxoSmithKline?
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 7:40AM CDT
SOURCE: GLAXOSMITHKLINE PLC. GlaxoSmithKline plc generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent...
DVAX: 10.91 (-5.03), GSK: 44.26 (+1.28)
Downgrade Alert for Dynavax Technologies (DVAX)
Comtex SmarTrend(R) - Fri Apr 29, 4:01AM CDT
Dynavax Technologies (NASDAQVAX) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $17.53 on volume of 1.1 million shares, above average daily volume of 901,000. Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
DVAX: 10.91 (-5.03)
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Dynavax Technologies Corporation and Advises Investors to Contact the Firm
BusinessWire - Fri Sep 02, 6:51PM CDT
Goldberg Law PC announces that it is investigating Dynavax Technologies Corporation ("Dynavax" or the "Company"
(Nasdaq: DVAX) concerning possible violations of federal securities laws. DVAX: 10.91 (-5.03)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Dynavax Technologies Corporation - DVAX
BusinessWire - Fri Sep 02, 5:25PM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dynavax Technologies Corporation (NASDAQ
VAX) resulting from allegations that Dynavax may have issued materially misleading business information to the investing public. DVAX: 10.91 (-5.03)
Dynavax Reports Second Quarter 2016 Financial Results
Marketwire Canada - Fri Aug 05, 4:52PM CDT
BERKELEY, CA--(Marketwired - August 05, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016.
DVAX: 10.91 (-5.03)
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Marketwire Canada - Fri Aug 05, 4:32PM CDT
Advisory Committee Meeting Scheduled for November 16, 2016
DVAX: 10.91 (-5.03)
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 10.91 (-5.03), HRTX: 17.70 (-0.63), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)
Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 10.91 (-5.03), JNJ: 119.32 (+0.24), HRTX: 17.70 (-0.63), GILD: 76.89 (-0.53), LJPC: 16.15 (-0.33), PETX: 8.81 (-0.11)
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
Marketwired - Sat Jun 11, 10:00AM CDT
Pivotal Phase 3 Data Show Investigational Two-Dose Hepatitis B Vaccine Provides a Significantly Higher Rate of Seroprotection Than an Approved Vaccine in Patients With Type 2 Diabetes
DVAX: 10.91 (-5.03)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 10.91 (-5.03), PACB: 8.28 (-0.02), AVXL: 3.05 (+0.02), PPHM: 0.38 (+0.02)
Dynavax to Present at Two Upcoming Investor Conferences
Marketwired - Wed May 18, 6:01AM CDT
BERKELEY, CA--(Marketwired - May 18, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows:
DVAX: 10.91 (-5.03)
Dynavax Technologies Down 16.5% Since SmarTrend Downtrend Call (DVAX)
Comtex SmarTrend(R) - Fri May 13, 1:38PM CDT
SmarTrend identified a Downtrend for Dynavax Technologies (NASDAQ
VAX) on April 27th, 2016 at $18.36. In approximately 2 weeks, Dynavax Technologies has returned 16.54% as of today's recent price of $15.32. DVAX: 10.91 (-5.03)
Dynavax Technologies reports 1Q loss
Automated Insights - Mon May 09, 8:05AM CDT
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Monday reported a loss of $27 million in its first quarter.
DVAX: 10.91 (-5.03)
Dynavax Reports First Quarter 2016 Financial Results
Marketwire Canada - Mon May 09, 8:02AM CDT
BERKELEY, CA--(Marketwired - May 09, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.
DVAX: 10.91 (-5.03)
Does This Upstart Pose a Threat to GlaxoSmithKline?
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 7:40AM CDT
SOURCE: GLAXOSMITHKLINE PLC. GlaxoSmithKline plc generates more than $1.2 billion per quarter selling vaccines that are used to treat infectious disease, and one of GlaxoSmithKline's top-selling vaccines is Engerix-B, a vaccine used to prevent...
DVAX: 10.91 (-5.03), GSK: 44.26 (+1.28)
Downgrade Alert for Dynavax Technologies (DVAX)
Comtex SmarTrend(R) - Fri Apr 29, 4:01AM CDT
Dynavax Technologies (NASDAQ
VAX) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $17.53 on volume of 1.1 million shares, above average daily volume of 901,000. Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways. DVAX: 10.91 (-5.03)
(0)
(0)Scroll down for more posts ▼